Research programme: dengue fever nanoparticle therapies - NanoViricides/Walter Reed Army Institute of Research
Alternative Names: DengiCide™; DengueCide™Latest Information Update: 28 Nov 2020
At a glance
- Originator NanoViricides; Walter Reed Army Institute of Research
- Developer NanoViricides; University of California at Berkeley; Walter Reed Army Institute of Research
- Class Antivirals; Polymers
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Dengue
Most Recent Events
- 28 Nov 2020 No recent reports of development identified for preclinical development in Dengue in USA
- 26 Nov 2018 Preclinical development is ongoing in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Dengue in USA